- Dr. Sinead Stoneman and Dr. Sean Barbour
Learning Objectives:
- Review the pharmacology and mechanism of action of belimumab, as well as its immunologic and clinical rationale in lupus nephritis.
- Critically appraise the evidence base for belimumab in lupus nephritis, with emphasis on trial design, endpoints, efficacy and safety, subgroup analyses, and long-term kidney outcomes.
- Identify practical considerations for incorporating belimumab into clinical practice in BC.
- Review the logistics for funding belimumab for lupus nephritis through the BC Renal GN formulary, as of June 1 2025.
